Waters Corp (WAT)
368.16
+7.53
(+2.09%)
USD |
NYSE |
Dec 20, 16:00
367.85
-0.31
(-0.08%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 21.86B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 13.89% |
| Valuation | |
| PE Ratio | 35.13 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.530 |
| Price to Book Value | 13.64 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.139 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 44.27% |
Profile
| Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions. |
| URL | https://www.waters.com |
| Investor Relations URL | https://www.waters.com/waters/en_US/Investors/nav.htm?cid=134614445&locale=en_US |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 06, 2025 (est.) |
| Last Earnings Release | Nov. 01, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 26, 1996 |
Ratings
Profile
| Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions. |
| URL | https://www.waters.com |
| Investor Relations URL | https://www.waters.com/waters/en_US/Investors/nav.htm?cid=134614445&locale=en_US |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 06, 2025 (est.) |
| Last Earnings Release | Nov. 01, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 26, 1996 |